logo-novo

Help your patients get started with Saxenda®

Watch this video to help your patients learn how to use their Saxenda® pen

Demonstrate the first injection in the office to help patients get started
video placeholder
 
Simple, once-daily dosing at any time of day, independent of meals1

Adult patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day 1†

The dose escalation schedule should be used to reduce the likelihood of gastrointestinal symptoms.
Graph
QD = once daily.



  • If patients do not tolerate an increased dose during dose escalation, each step in the dose escalation can be delayed up to 7 days
  • If a patient has not lost at least 5% of their initial body weight after 12 weeks on the 3.0 mg maintenance dose, treatment with Saxenda® should be discontinued


Pediatric patients


  • Pediatric patients may follow a similar dose escalation schedule as for adults.
  • The dose should be increased until 3.0 mg (maintenance dose) or maximum tolerated dose has been reached.
    • Daily doses higher than 3.0 mg are not recommended.
    • Pediatric patients who do not tolerate 3 mg daily may have their maintenance dose reduced to 2.4 mg daily.
  • Discontinue Saxenda® if the patient cannot tolerate the 2.4 mg dose.
  • If pediatric patients do not tolerate an increased dose during dose escalation, the dose may also be lowered to the previous level.
    • Dose escalation for pediatric patients may take up to 8 weeks.
  • Evaluate the change in BMI after 12 weeks on the maintenance dose and discontinue Saxenda® if the patient has not had a reduction in BMI of at least 1% from baseline, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.


Missed dose1

Hunger
If a dose of Saxenda® is missed, the once-daily regimen should be resumed as prescribed with the next scheduled dose. An extra dose or increase in dose should not be taken to make up for the missed dose.

Based on the elimination half-life, patients should be advised to reinitiate Saxenda® at 0.6 mg if more than 3 days have elapsed since the last dose. This approach will mitigate any GI symptoms associated with reinitiation of treatment.

Tips for managing some of the most common GI side effects

Review these tips with your patients to help them manage some of the most common side effects seen with Saxenda®:
Graph

Starting a patient
on Saxenda®?

Request samples by clicking on the link below.
Saxenda product

Access patient and healthcare professional support materials and videos, and learn more about the SaxendaCare® Patient Support Program

† Please consult the Product Monograph for complete dosing information.
GI = gastrointestinal.

 

References:

  1. Saxenda® Product Monograph. Novo Nordisk Canada Inc. December 9, 2022.
  2. Ackley B. Nursing diagnosis handbook: An evidence-based guide to planning care. 9 ed: Elsevier Health Sciences; 2018.
  3. Mayo Clinic. Nausea and vomiting. Available at: http://www.mayoclinic.com/health/nausea/MY00572/DSECTION=when-to-see-a-doctor. Retrieved October 2020.

 

Contact Us  | Privacy Policy | Terms of Use


CA23SX00053E
Saxenda® is a registered trademark of Novo Nordisk A/S and used by Novo Nordisk Canada Inc. Novo Nordisk Canada Inc., Tel: (905) 629-4222 or 1-800-465-4334.

© Novo Nordisk Canada Inc.